Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT03146546

STUDY00015328: Sepsis Endotypes

Diagnostic and Prognostic Biomarkers to Elucidate Sepsis Endotypes

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Milton S. Hershey Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. We hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.

Detailed description

Day 1 Sample Collection: 20ml of blood for chemical and genetic biomarker analysis. ≤1ml of saliva, stool, and tracheal aspirate for inflammatory marker analysis. Quadratus lumborum muscle size measurement and CT abdomen correlation. If not part of routine care, additional blood tests for cell differential, procalcitonin, and inflammatory markers. Electronic Medical Records (EMR) Data: APACHE II and SOFA severity scores. Demographics, vital signs, inflammatory markers, organ dysfunction markers, and various blood chemistry values. Days 2-3 Daily Documentation: Record the most abnormal value for the same parameters as Day 1. Days 3-5 (Once) Sample Collection: Repeat of blood, saliva, stool, and tracheal aspirate collection. EMR data access for severity scores and other clinical parameters. Days 5-6 Daily Documentation: Continued recording of the most abnormal values for clinical parameters. Days 7-10 (Once) Sample Collection: Repeat of blood, saliva, stool, and tracheal aspirate collection. Measurement of muscle size and CT correlation. EMR data access for the same parameters as earlier. Day 14 (or Discharge) Final Sample Collection: 20ml of blood and other samples, with no more than 1 ml/kg of blood collected over the entire study. EMR and Clinical Data: Collection of severity scores, vital signs, inflammation markers, organ dysfunction markers, and other clinical variables. Day 30, 3 Months, 6 Months, and 1 Year Long-term Outcomes: EMR review for clinical outcomes such as date of death, re-hospitalization, persistent critical illness. Phone interviews to gather subjective data about the post-hospitalization course and complications.

Conditions

Timeline

Start date
2020-08-06
Primary completion
2026-06-30
Completion
2026-06-30
First posted
2017-05-10
Last updated
2025-09-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03146546. Inclusion in this directory is not an endorsement.